Copyright
©The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Hepatol. Apr 8, 2015; 7(4): 673-687
Published online Apr 8, 2015. doi: 10.4254/wjh.v7.i4.673
Published online Apr 8, 2015. doi: 10.4254/wjh.v7.i4.673
Recent advances in multidisciplinary management of hepatocellular carcinoma
Asmaa I Gomaa, Imam Waked, Hepatology Department, National Liver Institute, Menoufiya University, Shebeen El-Kom 35111, Egypt
Author contributions: Gomaa AI and Waked I reviewed the literature and wrote the manuscript.
Conflict-of-interest: None related to this work; Waked I is speaker for Roche HL, MSD, BMS, and Gilead; advisory board for Janssen, Roche HL, and MSD; investigator for Roche HL, BMS, Bayer, Janssen, AbbVie, and Gilead.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Asmaa I Gomaa, MD, Hepatology Department, National Liver Institute, Menoufiya University, Gamal Abd El-Nasir, Shebeen El-Kom 35111, Egypt. aibrahim@liver-eg.org
Telephone: +20-100-6157160 Fax: +20-48-2234586
Received: August 28, 2014
Peer-review started: August 28, 2014
First decision: November 27, 2014
Revised: December 17, 2014
Accepted: January 15, 2015
Article in press: January 19, 2015
Published online: April 8, 2015
Peer-review started: August 28, 2014
First decision: November 27, 2014
Revised: December 17, 2014
Accepted: January 15, 2015
Article in press: January 19, 2015
Published online: April 8, 2015
Core Tip
Core tip: This article reviews the available treatment options for hepatocellular carcinoma. The recent clinical trials of molecular-targeted therapies, as single agents or in combination with other treatments, are reviewed, and some future study directions are addressed. The importance of a multidisciplinary approach to management is highlighted.